{"Symbol": "IQV", "AssetType": "Common Stock", "Name": "IQVIA Holdings Inc", "Description": "IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.", "CIK": "1478242", "Exchange": "NYSE", "Currency": "USD", "Country": "USA", "Sector": "TRADE & SERVICES", "Industry": "SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH", "Address": "4820 EMPEROR BLVD., DURHAM, NC, US", "OfficialSite": "https://www.iqvia.com", "FiscalYearEnd": "December", "LatestQuarter": "2024-12-31", "MarketCapitalization": "25802983000", "EBITDA": "2921000000", "PERatio": "19.2", "PEGRatio": "0.755", "BookValue": "34.45", "DividendPerShare": "None", "DividendYield": "None", "EPS": "7.48", "RevenuePerShareTTM": "84.97", "ProfitMargin": "0.0891", "OperatingMarginTTM": "0.16", "ReturnOnAssetsTTM": "0.0532", "ReturnOnEquityTTM": "0.226", "RevenueTTM": "15405000000", "GrossProfitTTM": "5375000000", "DilutedEPSTTM": "7.48", "QuarterlyEarningsGrowthYOY": "-0.048", "QuarterlyRevenueGrowthYOY": "0.023", "AnalystTargetPrice": "221.31", "AnalystRatingStrongBuy": "5", "AnalystRatingBuy": "15", "AnalystRatingHold": "5", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "19.2", "ForwardPE": "11.86", "PriceToSalesRatioTTM": "1.675", "PriceToBookRatio": "4.104", "EVToRevenue": "2.416", "EVToEBITDA": "10.78", "Beta": "1.462", "52WeekHigh": "252.88", "52WeekLow": "135.97", "50DayMovingAverage": "178.83", "200DayMovingAverage": "209.86", "SharesOutstanding": "176315000", "DividendDate": "None", "ExDividendDate": "None"}